1[2]Roberts R M,Liu L,Guo Q,et al.The evolution of the type Ⅰinterferons [J].J Interferon Cytokine Res,1998,18:805-806.
2杨华.猪白细胞干扰素治疗小鹅瘟效果观察[J].中国兽医杂志,2000,(2):54-54.
3Giannelli G,Antonelli G,Fera G,et al. Biological and clinical significance of neutralizing and binding antibodies to α-IFN during therapy for chronic hepatitis C[J]. Clin Exp Exp Immunol,1994,97:4.
4Bendtzen K,Svenson M,Jonhson V,et al. Autoantibodies to cytokines-friends or foes?[J].Immunol Today(Lib Ed),1990,11:167.
5Nakoo K,Nakata K,Yamashita M,et al. P48(ISGF-3gamma) is involved in interferon-alpha induced suppression of hepatitis B virus enhancer-1 activity[J]. J Biol Chem,1999,274(40):28075.
6Brunetto M R,Oliver F,Colombatto P,et al. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha[J]. J Hepatol,1995,22(1 suppl):42.
7Marques A R,Lau D T,McKenzie R,et al. Combination therapy with famciclovir and interferon-α for the treatment of chronic hepatitis B[J]. J Infect Dis,1998,178(5):1483.
8Chen Q,Gong B,Mahmoud-Ahmed As,et al. Apo2L/TrAIL and Bcl-2-related proteins regulated type I interferon-induced apoptosis in mutiple myeloma[J].Blood,2001,98(7):2183.
9Edelbaum A,Stein D,Holland N,et al. Expression of active human interferon-beta in transgenic plants[J]. J Interferon Res,1992,12:449.
